A Phase 1 interventional study of Belzutifan and Phenytoin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers designed belzutifan, the study medicine, to treat certain kinds of cancer.
The goal of this study is to learn what happens to belzutifan in a healthy person's body over time when taken, by mouth, as a tablet. Researchers will learn what happens when belzutifan is taken alone and when it is taken after several days of treatment with phenytoin.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive belzutifan during study Period 1, followed by a washout period, then they receive belzutifan and phenytoin during study Period 2.
Drug: Belzutifan · Drug: Phenytoin
Oral administration
Also known as: MK-6482, PT2977, Welireg™
Oral administration
Also known as: Phenytoin sodium
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Belzutifan
Blood samples will be collected to determine the AUC0-inf of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 36 days
Number of Participants Who Discontinue Study Drug Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 22 days
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of Belzutifan in Plasma
Blood samples will be collected to determine the AUC0-last of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Area Under the Concentration-Time Curve from Time 0 to 24 Hours (AUC0-24) of Belzutifan in Plasma
Blood samples will be collected to determine the AUC0-24 of belzutifan.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Maximum Plasma Concentration (Cmax) of Belzutifan in Plasma
Blood samples will be collected to determine the Cmax of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Plasma Concentration 24 Hours Postdose (C24) of Belzutifan in Plasma
Blood samples will be collected to determine the C24 of belzutifan.
Time frame: 24 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Belzutifan in Plasma
Blood samples will be collected to determine the Tmax of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Apparent Terminal Half-life (t1/2) of Belzutifan in Plasma
Blood samples will be collected to determine the t1/2 of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Apparent Clearance (CL/F) of Belzutifan in Plasma
Blood samples will be collected to determine the CL/F of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Apparent Volume of Distribution during terminal phase (Vz/F) of Belzutifan in Plasma
Blood samples will be collected to determine the Vz/F of belzutifan.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2025 to primary completion in May 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Belzutifan · Phenytoin